Company news

Kezar Life Sciences, Inc. news in 2025

Kezar Life Sciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

November 12, 2025

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

November 7, 2025

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

October 16, 2025

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

August 28, 2025

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

August 13, 2025

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

July 15, 2025

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

March 25, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

March 24, 2025

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

February 18, 2025

Decks in 2025